CHOZN® GS-/- Perfusion Cell Line Development For Intensified Processes

The biopharmaceutical industry is undergoing a significant transformation as it shifts towards continuous and intensified upstream bioprocesses, moving away from the traditional fed-batch-based production processes. This paradigm shift is driven by evolving industry demands, which underscore the necessity for key innovations to meet manufacturing expectations and facilitate the successful transition to intensified processes. Additionally, there is an increasing number of modalities in the development pipeline and a growing desire to manufacture regionally in smaller facilities. These facilities must be capable of handling intensified processes, particularly for biosimilars and new therapies that cater to smaller patient populations. As a result of these market drivers, there are three primary goals of upstream process intensification. The first goal is to increase process speed, which involves accelerating the upstream process from the seed train to downstream purification. The second goal is to enhance productivity by boosting protein titer and harvest yield. Finally, the third goal is to improve product quality, ensuring the highest product quality with minimal process impurities.

Discover why these objectives are crucial for the biopharmaceutical industry to meet the demands of modern healthcare and deliver innovative therapies efficiently and effectively.